The UK and US have secured a important commercial pact that will preserve no import taxes on British drug shipments entering the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these vital products will remain at nothing for a timeframe of the next three years.
This development follows recent threats to hike import taxes on patented drug products, with figures mentioned up to double the cost.
"This agreement with the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a statement noted.
Trade Significance
Drugs are one of the the United Kingdom's biggest export categories to the US, which is by far the primary buyer for large British pharmaceutical firms.
Export figures indicate that in the year to the end of the third quarter, the UK exported medicines worth £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards employment, boosts funding and paves the way for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal entails several key pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to increase overall public funding on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be restricted at fifteen percent. Previously, rebates topped 20%.
Industry Background
The deal takes place against a long-running dispute between the sector and the UK government over medicine costs and approval rates.
The disagreement were heightened by claims that American consumers were paying significantly more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
